GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia. 

Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology to deepen our understanding of biological mechanisms and target the underlying drivers of neurodegenerative diseases.  

“We’re exploring innovative treatment approaches to develop breakthrough medicines for patients and we’re investigating whether vaccines like RZV might play a role in reducing dementia risk. The data we are presenting at AAIC reflects our commitment to advance the science behind neurodegeneration.” 

RSV and dementia risk evidence

Three GSK-sponsored, real-world studies on shingles vaccination and dementia risk were presented. 

In a study of adults aged 65 and older within an integrated healthcare system in Southern California (Epi-Z-103), 65,800 individuals vaccinated with two doses of RZV were matched 1:4 with 263,200 unvaccinated individuals on age, sex, race/ethnicity, and history of immunisation with Zoster Vaccine Live (ZVL).  

Data showed that individuals that received two doses of RZV had a statistically significant reduction of dementia risk (51% lower risk of dementia compared to unvaccinated individuals; 27% lower dementia risk compared to individuals who received a tetanus, diphtheria, and pertussis vaccine (Tdap)). 

In a study of US Medicare beneficiaries aged 65 and older (Epi-Z-108), 502,845 individuals received two doses of RZV and were matched 2:1 with 1,005,690 unvaccinated individuals. Individuals vaccinated with two doses of RZV had a statistically significant reduction of dementia risk (33% lower risk of all- cause dementia compared to unvaccinated individuals who attended at least one preventive care visit). 

In a study of adults aged 65-74 in the UK Biobank cohort, 10,508 individuals with at least one dose of shingles vaccine (Zoster Vaccine Live) were matched 1:5 with 52,540 unvaccinated individuals on age, sex, and APOE-e4 Carrier status, an established genetic risk factor for Alzheimer’s disease.  

Results showed there was no statistical evidence of a difference in vaccine effect between individuals who carry the APOE-e4 haplotype and those that do not. Additionally, results show a statistically significant 32% lower risk for dementia among individuals receiving HZ-Vx compared to adults not vaccinated with HZ-Vx.

Diana Turner, Senior Digital Content Editor, DDW